Clinical Trial: Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Phase II Study of Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in the Treatment of High Grade Neuroendocrine Carcinoma
Brief Summary: carboplatin and etoposide, followed by maintenance therapy with weekly paclitaxel in patients with poorly differentiated neuroendocrine carcinomas. We hope to identify a "standard treatment" for this unusual group of patients who are not usually eligible for clinical trials.
Detailed Summary:
Upon determination of eligibility, patients will be receive:
- Paclitaxel + Carboplatin + Etoposide
Sponsor: SCRI Development Innovations, LLC
Current Primary Outcome: Overall response
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Overall survival
- Time to progression
- Overall toxicity
Original Secondary Outcome: Same as current
Information By: SCRI Development Innovations, LLC
Dates:
Date Received: September 12, 2005
Date Started: December 1998
Date Completion:
Last Updated: June 28, 2010
Last Verified: October 2008